Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

OBJECTIVES: A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) in uninfected adult volunteers. METHODS: Participants were randomized (3:1) to S...

Descripción completa

Detalles Bibliográficos
Autores principales: Isa, Flonza, Forleo-Neto, Eduardo, Meyer, Jonathan, Zheng, Wenjun, Rasmussen, Scott, Armas, Danielle, Oshita, Masaru, Brinson, Cynthia, Folkerth, Steven, Faria, Lori, Heirman, Ingeborg, Sarkar, Neena, Musser, Bret J., Bansal, Shikha, O'Brien, Meagan P., Turner, Kenneth C., Ganguly, Samit, Mahmood, Adnan, Dupljak, Ajla, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Kowal, Bari, Soo, Yuhwen, Geba, Gregory P., Lipsich, Leah, Braunstein, Ned, Yancopoulos, George D., Weinreich, David M., Herman, Gary A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249725/
https://www.ncbi.nlm.nih.gov/pubmed/35788416
http://dx.doi.org/10.1016/j.ijid.2022.06.045

Ejemplares similares

Ejemplares similares